Swarms of bugs, missing data plague firms now making heart drug
Last month, the FDA posted a list of 43 versions of valsartan and similar drugs that don ’t contain carcinogens. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2019 Category: Pharmaceuticals Source Type: news
More Losartan Joins Recall List, Heritage Pharma Distributors More Losartan Joins Recall List, Heritage Pharma Distributors
Manufacturer Vivimed has recalled 19 lots of its losartan potassium found with the same potential carcinogen that has led to recalls of both losartan and valsartan from various companies.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Exforge (Amlodipine and Valsartan) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 3, 2019 Category: Drugs & Pharmacology Source Type: news
Laboratory analysis of valsartan products
FDA continues to investigate the presence of impurities in valsartan products and other angiotensin II receptor blockers (ARBs) used to treat high blood pressure and heart failure. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 3, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
More Questions and Answers: Impurities Found in Certain Angiotensin II Receptor Blocker (ARB) products
Answers to questions about nitrosamine impurities found in valsartan, losartan, and irbesartan and FDA's actions to address the issue (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 27, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Search List of Recalled Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan
Find out which specific blood pressure medications are affected by the recall (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 27, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Recalls of Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan
Get current information about recalls of blood pressure medications: valsartan, losartan, and irbesartan (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 27, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)
Get updates on the recalls (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 27, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications
FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 27, 2019 Category: American Health Authors: FDA Source Type: news
Dozens sue over Chinese-made blood pressure drug they claim gave them cancer
Following massive recalls of valsartan blood pressure drugs, thousands of lawsuits claiming it gave patients cancer have been filed against the Chinese manufacturer at fault, Bloomberg reported. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2019 Category: Consumer Health News Source Type: news
Recall Of Blood Pressure Drug Losartan Expanded
(CNN) — If you take blood pressure medicine, you’ll want to double-check your bottle. Torrent Pharmaceuticals Ltd. has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets.
Tests found trace amounts of a potentially cancer-causing impurity called N-methylnitrosobutyric acid in some of these drugs. The company is recalling 36 additional lots, it said Thursday.
A full list of recalled drugs is available on the US Food and Drug Administration website.
Some of the recalled blood pressure medication (Image credit: FDA)
The company hasn’t had any reports of users getting ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News losartan Source Type: news
FDA urges patients to keep taking contaminated blood pressure drugs
Many valsartan-containing drugs have been recalled for a carcinogen. Amid shortages of untainted drugs, the FDA says not taking them poses a greater risk than the low levels of carcinogen does. (Source: the Mail online | Health)
Source: the Mail online | Health - April 5, 2019 Category: Consumer Health News Source Type: news
Blood pressure patients can take tainted pills during valsartan shortage, FDA says
Due to a shortage of certain commonly used blood pressure drugs, the US Food and Drug Administration took the unusual step Thursday of reminding patients that they have access to available -- if tainted -- medicines while a fresh supply of uncontaminated pills is manufactured. (Source: CNN.com - Health)
Source: CNN.com - Health - April 4, 2019 Category: Consumer Health News Source Type: news
Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the agency ’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue
FDA announces list of nitrosamine-free ARB medications confirmed by the agency to help patients and healthcare providers (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 4, 2019 Category: American Health Source Type: news
PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains
Failure to start therapy in hospital is a ' lost opportunity, ' say researchers from evidence that such early sacubitril/valsartan bested enalapril more in the earliest weeks after discharge than later.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
